^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type

Published date:
09/14/2020
Excerpt:
RAM+ERL-treated pts with ex21 mut had similar treatment benefit as pts with ex19 mut...These results support RAM+ERL as a first-line therapy for both ex19 and ex21-positive met NSCLC.
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

Excerpt:
Eligible for first-line treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation].
Trial ID: